DrinabantAlso known as AVE1625
Sanofi-Aventis CB1 antagonist; in volunteers it inhibited THC effects from 20 mg, with no effect of its own.
C₂₃H₂₀Cl₂F₂N₂O₂S
CAS 358970-97-5
- Family
- ECS pharmacological toolAntagonist or inverse agonist
- Molar mass
- 497.40 g/mol
Updated on
In plain terms
Drinabant is a blocker of the CB1 receptor, that is, the opposite of a cannabinoid. In volunteers it reduced several effects of THC from 20 mg, which shows it reaches the brain. No marketing authorisation was found: it remains a study molecule.
Receptors and activity
Target network
- Blocks or inhibits
The lower the cited value, the closer the target sits to Drinabant: one ring per factor of 100. A target with no measured value stays on the edge.
Where these targets live
Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of Drinabant.
CB1CB1 found in 7 regions of the body
- Basal gangliadenseMost dense in basal ganglia outflow nuclei1
- CerebellumdenseVery dense in the cerebellum1
- HippocampusdenseVery high concentrations in the hippocampus2
- AmygdaladenseHigh concentrations in the amygdala2
- CortexpresentPresent throughout the neocortex2
- Adipose tissuepresentExpressed in adipose tissue3
- GutpresentColonic epithelium, smooth muscle and plexus4
Map sources
- Herkenham M et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A, 1990 (new tab)
- Glass M et al. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997 (new tab)
- Engeli S et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes, 2005 (new tab)
- Wright K et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005 (new tab)
Cited values
- CB1Antagonistno measured value cited
Central antagonism in humans: from 20 mg, inhibition of most of the effects of Δ9-THC; no affinity value (Ki or IC50) found (Zuurman et al. 2010)
Measured effects
Not characterised. No placebo-controlled human trial has measured the effects of Drinabant, so no level is shown.
Levels computed from placebo-controlled human trials: difference from placebo on 100, at the dose and route stated. Read the method
Pharmacology
Drinabant, known by the code AVE1625, is a CB1 receptor antagonist developed by Sanofi-Aventis in the wave of research on this target for obesity, smoking cessation and cognitive impairment (Zuurman et al. 2010). In rats it increased lipolysis, reduced liver glycogen and raised energy expenditure and fat oxidation, independently of reduced food intake (Herling et al. 2007). Zuurman and colleagues used it with Δ9-THC as a probe in volunteers: from 20 mg it inhibited most THC effects, with no effect of its own on psychological or behavioural parameters or heart rate. In rodents, given intraperitoneally (1, 3 and 10 mg/kg), it reversed the abnormally persistent latent inhibition induced by MK-801 or neonatal nitric oxide synthase inhibition and improved working and episodic memory; it did not diminish the efficacy of antipsychotics, reduced the catalepsy and weight gain they cause and, unlike other CB1 antagonists, produced no anxiogenic-like effects (Black et al. 2011). These studies are preclinical or limited to healthy volunteers. According to the trade press, Sanofi ran an oral phase I and II programme, including a phase II trial in cognitive impairment in schizophrenia terminated in 2016 for insufficient efficacy (GEN, 27 December 2018); the licence granted to Opiant at the end of 2018 targeted acute cannabinoid overdose.
Key sources.
- Herling AW et al. CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am J Physiol Endocrinol Metab, 2007 (new tab)PMID 17595216
- Zuurman L et al. Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625. J Psychopharmacol, 2010 (new tab)PMID 18801827
- Black MD et al. AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology (Berl), 2011 (new tab)PMID 21181124
- Meye FJ et al. Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol Psychiatry, 2013 (new tab)PMID 23070073
- GEN, Opiant to develop Sanofi's acute cannabinoid overdose candidate drinabant, 27 December 2018 (trade press) (new tab)
- PubChem, drinabant, CID 10278470 (identifiers and properties) (new tab)
History
- Source
- An entirely synthetic compound with no natural occurrence. It was designed by Sanofi-Aventis as a drug candidate (Herling et al. 2007); no marketing authorisation was found.
Origin
Research tool
No known biological pathway: drinabant is a synthetic compound, an azetidine bearing a bis(4-chlorophenyl)methyl group and a methanesulfonamide function, unrelated to the plant cannabinoid pathway.
Legal framework
- European Union
The substance is not listed in the Annex to Council Framework Decision 2004/757/JHA (consolidated version of 12 January 2026), which lists the new psychoactive substances controlled at European Union level; control is a matter for national law. It is not listed in the schedules of the 1971 Convention on Psychotropic Substances (INCB Green List, 36th edition, 2025, text reviewed). No marketing authorisation was found.
- France
Not classified: drinabant is not on the ANSM consolidated list of narcotics (updated 16/02/2026) and this azetidine sulfonamide derivative falls within none of the generic families of that list. No marketing authorisation was found.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
Classification
Family, origin and source verification
- Family
ECS pharmacological tool › Antagonist or inverse agonist
- Verification
Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.
- Wikipedia (English)
Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.
References
- Herling AW et al. CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am J Physiol Endocrinol Metab, 2007 (new tab)PMID 17595216
- Zuurman L et al. Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625. J Psychopharmacol, 2010 (new tab)PMID 18801827
- Black MD et al. AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents. Psychopharmacology (Berl), 2011 (new tab)PMID 21181124
- Meye FJ et al. Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol Psychiatry, 2013 (new tab)PMID 23070073
- GEN, Opiant to develop Sanofi's acute cannabinoid overdose candidate drinabant, 27 December 2018 (trade press) (new tab)
- PubChem, drinabant, CID 10278470 (identifiers and properties) (new tab)
Identifiers
Names
- Common name
- Drinabant (AVE1625)
- IUPAC name
- N-[1-[bis(4-chlorophenyl)methyl]azetidin-3-yl]-N-(3,5-difluorophenyl)methanesulfonamide
- Other names
- AVE1625 · drinabantum · AVE-1625
Identifiers
- Formula
- C₂₃H₂₀Cl₂F₂N₂O₂S
- CAS
- 358970-97-5
- PubChem CID
- 10278470(new tab)
- InChIKey
- IQQBRKLVEALROM-UHFFFAOYSA-N
- SMILES
- CS(=
O) (= O) N(C1CN(C1) C(C2= CC= C(C= C2) Cl) C3= CC= C(C= C3) Cl) C4= CC(= CC(= C4) F) F
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.